Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 March 2025 | Story Edzani Nephalela | Photo Lethabo Machabaphala
Theology MOU 2025
Prof Zorodzai Dube, Head of the Department of Religion Studies at the UFS, and Thabo Seotsanyana, representative for the African Centre of Excellence, formalised a collaboration to advance research into African spirituality.

The University of the Free State (UFS) Faculty of Theology and Religion recently made history as the first institution to partner with the African Centre of Excellence in a significant collaboration advancing research and education on African indigenous spirituality.

This partnership is set to foster a deeper understanding of African indigenous knowledge, highlighting its importance and addressing misconceptions about its practices.

The Memorandum of Understanding (MoU) signed between the parties outlines the facilitation of joint research and teaching initiatives. According to Prof Zorodzai Dube, Head of the Department of Religion Studies at the UFS, the MoU will provide UFS students with the unique opportunity to engage with African indigenous knowledge systems, particularly those related to herbs, healthcare, and traditional healing practices.

“The collaboration aims to enrich the students’ academic experience and provide them with critical insights into African indigenous spirituality,” Prof Dube said. “Furthermore, this partnership is seen as a key step toward furthering UFS’s vision to become a leading institution in research, including Africanisation and pan-African research.” He added that the faculty views this collaboration as a springboard for strengthening its position as a leader in addressing Africa-related issues in education and research.

Significance of this partnership

Thabo Seotsanyana, Curriculum Developer for the African Centre of Excellence, emphasised that this partnership will challenge long-standing misconceptions about African spirituality while fostering a deeper appreciation for its value and relevance in contemporary society. “This collaboration is a landmark event for several reasons. It emphasises the importance of African indigenous spirituality in academic discourse and provides a platform for decolonising knowledge systems.”

In his address, Seotsanyana highlighted that the African Hidden Voices is committed to transforming mindsets, particularly within African nations. He spoke about how generations have been influenced by ideologies that dismiss African spiritual practices in favour of foreign belief systems, and how this partnership aims to reverse that trend.

“We are delighted to be signing a Memorandum of Understanding with one of the most highly regarded institutions in South Africa,” Seotsanyana shared, reading a message from Imboni Dr uZwi-Lezwe Radebe, founder of African Hidden Voices. “This marks a significant milestone in our history that will be remembered for years.”

Impact on future generations

Seotsanyana highlighted that the organisation is dedicated to educating individuals about African spirituality, fostering African leadership, and embracing traditional African ways of life.

“Our mission is to nurture a new generation that understands, values, and actively engages with African spirituality,” he explained. “This initiative marks a significant step in the academic exploration and preservation of African indigenous spirituality. It aims to leave a lasting legacy that inspires future generations to reconnect with their heritage, challenge outdated views, and adopt an inclusive, spiritually enriched way of life. This aligns with the University of the Free State’s Vision 130, which promotes inclusivity and ethical values, ensuring that everyone feels represented, welcomed, and has access to the university’s resources.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept